Ribavirin: Clinical Trials

271 trials of Ribavirin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

222 completed, 18 terminated, 15 unknown, 11 withdrawn. 271 Phase 2, 25 Phase 3, 19 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 2271Completed 222, Terminated 18, Unknown 15, Withdrawn 11, Recruiting 3, Not yet recruiting 1, Suspended 1
Phase 325Completed 16, Unknown 4, Withdrawn 2, Not yet recruiting 1, Recruiting 1, Terminated 1
Phase 119Completed 12, Terminated 5, Unknown 2

Follow Ribavirin: new trials by email Literature Review of Ribavirin trials Research Report on Ribavirin

Trials (filtered) newest first · largest first

All 271 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Treatment of CKD Patients With HCV
SOF+DCV, OBV/PTV/r) ± ribavirin (RBV) - HCV Infection ( Genotype 4) in CKD Patients
Phase 2 / Phase 3Not yet recruitingTanta University502026-09-152026-08-20
ISTH/ANRS 0409s INTEGRATE Lassa Fever Study
Favipiravir, Ribavirin, Dexamethasone - Lassa Fever
Phase 2 / Phase 3RecruitingIrrua Specialist Teaching Hospital17552025-05-022026-02-04
Assessing Antiviral Treatments in Early Symptomatic RSV
Ribavirin, Molnupiravir, Favipiravir - Respiratory Syncytial Virus, Respiratory Syncytial Virus, Human
Phase 2RecruitingUniversity of Oxford10002024-07-252025-07-02
LAssa Fever Adjunct Treatment With DEXamethasone
Dexamethasone, Ribavirin - Lassa Fever
Phase 2RecruitingBernhard Nocht Institute for Tropical Medicine422024-02-052025-02-06
UMIT-1 Trial Favipiravir & Ribavirin for the Treatment of CCHF
Favipiravir, Ribavirin - CCHF
Phase 1 / Phase 2UnknownLiverpool School of Tropical Medicine242023-07-122023-10-05
Treatment of Hemorrhagic Fever With Ribavirin
Virazole - Hemorrhagic Fever
Phase 2SuspendedU.S. Army Medical Research and Development Command502022-10-312026-07-07
Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19
Ribavirin Capsules, Favipiravir - SARS-CoV2, COVID-19
Phase 2 / Phase 3UnknownThe Scientific and Technological Research Council of Turkey1002021-04-012021-04-02
A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19
Nitazoxanide, Placebo Nitazoxanide, Ribavirin - SARS-CoV Infection, Covid19
Phase 2TerminatedRutgers, The State University of New Jersey72020-12-022022-05-05
IFN Beta-1b and Ribavirin for Covid-19
Interferon beta-1b, Ribavirin - Covid19
Phase 2UnknownThe University of Hong Kong962020-07-292020-07-31
Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment
Lopinavir/ritonavir, Ribavirin, Interferon Beta-1B - Novel Coronavirus Infection
Phase 2CompletedThe University of Hong Kong1272020-02-102020-04-15
A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Brequinar/Brequinar + Ribavirin - Acute Myeloid Leukemia
Phase 1 / Phase 2TerminatedClear Creek Bio, Inc.172018-12-202022-08-08
The Diabetes Virus Detection and Intervention Trial
Ribavirin + Pleconaril, Placebos - Type1 Diabetes Mellitus, Enterovirus
Phase 2CompletedOslo University Hospital962018-08-302021-04-08
Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.
Ravidasvir, Danoprevir, Ritonavir - HCV
Phase 2 / Phase 3CompletedAscletis Pharmaceuticals Co., Ltd.4252017-07-012020-07-28
Ombitasvir /Paritaprevir/Ritonavir Plus Ribavirin on HCV GT4
OBV/PTV/r) ± ribavirin (RBV) - Hepatitis C Virus Infection
Phase 1 / Phase 2CompletedBeni-Suef University1002017-01-052020-05-12
Pembrolizumab (MK-3475) in Hepatocellular Carcinoma
Elbasvir/Grazoprevir, Laboratory Biomarker Analysis, Pembrolizumab - BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
Phase 2CompletedM.D. Anderson Cancer Center152016-12-092025-07-15
Safety and Efficacy of Gratisovir (Sofosbuvir)- Ribavirin Therapy in Pediatric Patients
Sofosbuvir Oral Product, Ribavirin - Pharmacological Action
Phase 2 / Phase 3UnknownNational Liver Institute, Egypt412016-12-012016-12-19
Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041)
Uprifosbuvir, Ruzasvir, Ribavirin - Hepatitis C
Phase 2TerminatedMerck Sharp & Dohme LLC2822016-11-162021-02-02
A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection
Faldaprevir, TD-6450, Ribavirin - Hepatitis C Viral Infection, Chronic Hepatitis C
Phase 2CompletedTrek Therapeutics, PBC252016-05-012017-10-17
Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4
(SOF and DCV), (SOF, DCV, and RBV) - Chronic Hepatitis C Virus Infection
Phase 2 / Phase 3CompletedBeni-Suef University9462016-04-012020-05-15
12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF
Ledipasvir/sofosbuvir, Ribavirin - HIV-1 Infection, Hepatitis C
Phase 2TerminatedAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections72016-02-172018-05-02

Showing 20 of 271. Sign in to see all of them.

Conditions studied

Hepatitis C (153)  ·  Hepatitis C, Chronic (115)  ·  HIV Infections (19)  ·  Hepatitis (14)  ·  Liver Diseases (8)  ·  Bronchiolitis Obliterans Syndrome (4)  ·  Hemorrhagic Fevers, Viral (4)  ·  Leukemia, Myeloid, Acute (4)  ·  COVID-19 (3)  ·  Hepatitis, Chronic (3)  ·  Infections (3)  ·  Influenza, Human (3)  ·  Lassa Fever (3)  ·  Virus Diseases (3)  ·  Anemia (2)

Sponsors

Merck Sharp & Dohme LLC (24)  ·  Gilead Sciences (22)  ·  Bristol-Myers Squibb (21)  ·  Hoffmann-La Roche (18)  ·  Vertex Pharmaceuticals Incorporated (14)  ·  AbbVie (11)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (11)  ·  AbbVie (prior sponsor, Abbott) (10)  ·  ANRS, Emerging Infectious Diseases (9)  ·  Boehringer Ingelheim (5)  ·  Debiopharm International SA (4)  ·  Jewish General Hospital (4)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (4)  ·  U.S. Army Medical Research and Development Command (4)  ·  Ascletis Pharmaceuticals Co., Ltd. (3)

Countries

United States (133)  ·  France (55)  ·  Puerto Rico (52)  ·  Germany (49)  ·  Canada (38)  ·  Spain (27)  ·  Australia (26)  ·  United Kingdom (24)  ·  Italy (21)  ·  Belgium (17)  ·  New Zealand (17)  ·  Austria (16)  ·  Poland (16)  ·  Egypt (8)  ·  Romania (7)

Top investigators

Robert H. Hyland, DPhil (5)  ·  Daniel Cohen, MD (4)  ·  Erin Castelloe, MD (3)  ·  John McNally, PhD (3)  ·  Raymond Chung, MD (3)  ·  Sarit Assouline, MD (3)

Results publications

PMID 24154738, PMID 24982088, PMID 25164700, PMID 25445400, PMID 26596948, PMID 26752189, PMID 28193518, PMID 28802814, PMID 28802816, PMID 30012435, PMID 30923816, PMID 30977945, PMID 31568620, PMID 15282352, PMID 15316341, PMID 15374882, PMID 15563253, PMID 15667486, PMID 15685543, PMID 15820563, PMID 15867490, PMID 16115185, PMID 16439867, PMID 16544259, PMID 16987047, PMID 17058240, PMID 17147494, PMID 17263626, PMID 17721093, PMID 18184077, PMID 18435468, PMID 18666223, PMID 19143532, PMID 19268724, PMID 19403902, PMID 19403903, PMID 19447518, PMID 19594300, PMID 19797971, PMID 19852040, PMID 19898214, PMID 20375406, PMID 20622678, PMID 20677940, PMID 20684729, PMID 20692693, PMID 20721883, PMID 20854821, PMID 20921898, PMID 21079746

NIH funding

2009 (8), 2014 (7), 2015 (7), 2008 (3), 2004 (1), 2005 (1), 2016 (1), 2023 (1), R01AI049141 (1), R01AI049508 (1), R01DA026727 (1), U01AI068636 (1), U01DK062444 (1), U01DK062467 (1), U01DK062483 (1)